Lupus Market Outlook 2031
The global lupus market size was USD 3.30 Billion in 2022 and is estimated to reach USD 7.97 Billion by 2031 register a high CAGR 10.3% during the forecast period, between 2023 to 2031. Lupus is a chronic autoimmune disease that causes widespread inflammation throughout the body.
The immune system of patients suffering from the disease are normally weaken due to the attacks of the cells on its own tissues causing damage to the heart, kidney, brain, joints, skin, lungs, and blood vessels. It is a type of disease that can affect every organ of the patient body. Some of the major lupus symptoms include adnominal pain, arthritis, headaches, kidney disease, hair loss, rashes, and more. A patient's treatment and diagnosis is different depending on the type of lupus and the results of blood tests.
Lupus Market Trends, Drivers, Restraints, and Opportunities:
- Rising prevalence of lupus as well as growing R&D activities to develop innovative treatment methods and techniques are key factors driving the market growth.
- Growing awareness of the disease along with increasing demand for advanced lupus treatment and diagnostics act as major drivers of the market.
- Stringent regulatory guidelines for approval of new drugs and high prices of lupus treatment drugs are expected to be major barriers to market expansion in the coming years.
- Expansion of clinical trials, new product development, and combination therapy studies undertaken by key players are key growth opportunities of the market expansion in the coming years.
Scope of the Lupus Market Report:
The report on the global lupus market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Lupus Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016 - 2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Techniques (Cutaneous Lupus Erythematosus, Drug-induced Lupus Erythematosus, Neonatal Lupus, and Systemic Lupus Erythematosus), Products (Antimalarial Drugs, Biologics, Corticosteroids, Immunosuppressants, Nonsteroidal Anti-inflammatory Drugs, and Others), End-Users (Diagnostic Laboratories, Hospital & Clinics, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
|
Key Players Covered
|
Aurinia Pharmaceuticals; F. Hoffmann-La; Bayer AG; GlaxoSmithKline plc; Mylan N.V.; Sandoz International GmbH; Bristol-Myers Squibb; Pfizer, Inc.; Cadila Healthcare; Sanofi; Lycera Corporation; Merck KGaA; Novartis AG; ImmuPharma LLC; and Trinity Biotech
|
Lupus Market Segment Insights:
Systemic lupus erythematosus segment to hold significant market share
Based on techniques, the global lupus market is segregated into cutaneous lupus erythematosus, drug-induced lupus erythematosus, neonatal lupus, and systemic lupus erythematosus. The systemic lupus erythematosus segment is projected to hold significant market share owing to wide adoption of the technique for the disease treatment.
This treatment can assist in managing symptoms and avoid other lupus-related health issues such as flare-ups. The involvement of large biopharmaceutical companies in drugs that are currently in clinical trials is likely to boost the segment growth in the coming years. Moreover, the growing burden of autoimmune diseases is a key driver of the segment.
Biologics segment to account for a substantial share
On the basis of products, the market is segmented into antimalarial drugs, biologics, corticosteroids, immunosuppressants, nonsteroidal anti-inflammatory drugs, and others. The biologics segment is anticipated to account for a substantial share owing to the development of new biologics with better efficacy, such as Rituximab and Benlysta, and several biologics are currently in the final stages of development.
The immunosuppressants segment, however, is projected to expand at a robust growth pace in the coming years attributed to the widespread use of methotrexate due to its inexpensive prices of the product.
Hospitals & clinics segment to register a substantial growth rate
In terms of end-users, the global lupus market is segmented into diagnostic laboratories, hospital & clinics, and others. The hospitals & clinics segment is expected to register a substantial growth rate during the forecast period due to the increasing prevalence of the disease, extensive research activities, and wide testing in hospitals and clinics.
Moreover, the presence of medical experts in hospitals and clinics for the diagnosis of the disease present another key driver of the segment.
North America is expected to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the market in the coming years due to the availability of reimbursement facility and citizens' increased expenditure on healthcare in the region.
Moreover, the rising prevalence of lupus, the growing demand for better treatment options, and government lupus initiatives are key aspects for the regional market growth. On the other hand, the market of Asia Pacific is anticipated to expand at a robust pace in the near future due to increasing number of people in high-income groups and rising government funding for research activities.
Major biotechnology companies are currently outsourcing their product development services to countries such as India, Singapore, China, and Malaysia, which is propelling the market in this region.
Segments
By Techniques
- Cutaneous Lupus Erythematosus
- Drug-induced Lupus Erythematosus
- Neonatal Lupus
- Systemic Lupus Erythematosus
By Products
- Antimalarial Drugs
- Biologics
- Corticosteroids
- Immunosuppressants
- Nonsteroidal Anti-inflammatory Drugs
- Others
By End-Users
- Diagnostic Laboratories
- Hospital & Clinics
- Others
By Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
By Key Players
- Aurinia Pharmaceuticals
- F. Hoffmann-La
- Bayer AG
- GlaxoSmithKline plc
- Mylan N.V.
- Sandoz International GmbH
- Bristol-Myers Squibb
- Pfizer, Inc.
- Cadila Healthcare
- Sanofi
- Lycera Corporation
- Merck KGaA
- Novartis AG
- ImmuPharma LLC
- Trinity Biotech
Competitive Landscape
Key players in the global lupus market are Aurinia Pharmaceuticals; F. Hoffmann-La; Bayer AG; GlaxoSmithKline plc; Mylan N.V.; Sandoz International GmbH; Bristol-Myers Squibb; Pfizer, Inc.; Cadila Healthcare; Sanofi; Lycera Corporation; Merck KGaA; Novartis AG; ImmuPharma LLC; and Trinity Biotech.
These players have widely engaged in various market development strategies including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to strengthen their geographical presence and expand their customer base globally.
Request For Customization
Enquiry Before Buying
Speak With Analyst
